Cigna National Formulary Coverage Policy



Effective Date	4/1/2023
Next Review Date	4/1/2024

Drug Quantity Management – Per Days Topical Antibiotics for Acne – Clindamycin

Table of Contents

Product Identifier(s)

Effective 1/1/23 to 2/6/23: 108039

Effective 2/7/23: 65506

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

National Formulary Medical Necessity

Drugs Affected

- Cleocin T[®] (clindamycin phosphate 1% topical gel, 1% topical lotion, 1% topical solution generic)
- Clindagel® (clindamycin 1% topical gel, generic)
- Evoclin® (clindamycin phosphate 1% topical foam generic)

This Drug Quantity Management program has been developed to prevent stockpiling, misuse and/or overuse use of topical clindamycin products. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

Drug Quantity Limits

Product	Package Size	Retail Maximum Quantity per 30 Days	Home Delivery Maximum Quantity per 90 Days
Cleocin T [®] (clindamycin 1% topical gel, generic)	30 gram tube 60 gram tube	120 grams*	360 grams ^Ω
Cleocin T [®] (clindamycin 1% topical lotion, generic)	60 mL bottle	120 mL*	360 mL ^Ω
Cleocin T [®] (clindamycin 1% topical solution, generic)	30 mL bottle 60 mL bottle (generic only) 10 mg/mL single-use pledget applicators (Carton of 60) [generic only]	120 mL*	360 mL ^Ω
Clindagel [®] (clindamycin 1% topical gel, generic)	75 mL bottle	150 mL	450 mL
Evoclin [®] (clindamycin 1% topical foam, generic)	50 gram aerosol can 100 gram aerosol can	100 grams*	300 grams ^Ω

This is a quantity sufficient to cover 8% of the body surface area when applying twice daily for 30 days; Ω This is a quantity sufficient to cover 8% of the body surface area when applying twice daily for 90 days.

Criteria

Cigna covers quantities as medically necessary when the following criteria are met:

Clindamycin phosphate 1% lotion (Cleocin T, generic) – twice daily application

1. If the individual needs to treat acne on greater than 8% of their body surface area, approve the requested quantity, not to exceed 240 mL per 30 days at retail or 720 mL per 90 days at home delivery.

Clindamycin phosphate 1% gel (Cleocin T, generic) – twice daily application

 If the individual needs to treat acne on greater than 8% of their body surface area, approve the requested quantity, not to exceed 240 grams per 30 days at retail or 720 grams per 90 days at home delivery.

Clindamycin phosphate 1% solution (Cleocin T, generic) – twice daily application

1. If the individual needs to treat acne on greater than 8% of their body surface area, approve the requested quantity, not to exceed 240 mL per 30 days at retail or 720 mL per 90 days at home delivery.

Clindamycin phosphate 1% gel (Clindagel, generic) - once daily application

1. If the individual needs to treat acne on greater than 8% of their body surface area, approve the requested quantity, not to exceed 300 mL per 30 days at retail or 900 mL per 90 days at home delivery.

Clindamycin phosphate 1% foam (Evoclin, generic)

1. If the individual needs to treat acne on greater than 8% of their body surface area, approve the requested quantity, not to exceed 200 grams per 30 days at retail or 600 grams per 90 days at home delivery.

Conditions Not Covered

Any other exception is considered not medically necessary, including the following:

1. No overrides are recommended for use in compounded formulations.

Background

Overview

The topical clindamycin products are indicated for the treatment of acne vulgaris.1

Dosing/Availability

Clindamycin topical gel, lotion, and solution (Cleocin T, generic) may be applied twice daily to the affected area.¹ Clindamycin 1% topical gel (Cleocin T, generic) is supplied as a 30 g and 60 g tube; clindamycin 1% topical lotion (Cleocin T, generic) is supplied as a 60 mL bottle. Clindamycin 1% topical solution (Cleocin T, generic) is supplied as 30 mL and 60 mL (generic only) bottles and a carton of 60 single-use pledget applicators (10 mg/mL) [generic only].

Clindamycin topical gel (Clindagel, generic) may be applied once daily to the affected area.² Clindamycin 1% gel (Clindagel, generic) is supplied as a 75 mL bottle.

Clindamycin foam (Evoclin, generic) is applied once daily to affected areas; enough should be applied to cover the entire affected area.³ Clindamycin 1% foam (Evoclin, generic) is supplied as a 50 g or 100 g aerosol can.

Application Information

For topical product application, a standard measure, the finger-tip unit (FTU), is often used.⁴ One FTU is the amount of product that is squeezed out of a standard tube along an adult's fingertip. One FTU is equivalent to approximately 0.5 g and provides enough product to treat an area of skin that is twice the size of one adult hand, or approximately 2% of an adult's total body surface area (BSA). Based on the FTU method, 120 grams provides enough product to cover approximately 8% of the patient's BSA when applying two times daily for 30 days.

The most common areas for acne breakouts are the face, chest, shoulders and back.⁵ Typically, acne does not cover the entire surface area of the face, chest, shoulders and back, but appears in selected areas of each. A quantity of 120 mL or 120 gram of topical clindamycin would be enough to treat the entire face, shoulders, or upper chest.

References

- 1. Cleocin T 1% topical solution, gel, lotion [prescribing information]. New York, NY: Pfizer.; December 2019.
- 2. Clindagel 1% gel [prescribing information]. Bridgewater, NJ: Bausch Health; January 2020.
- 3. Evoclin 1% foam [prescribing information]. Morgantown, WV: Mylan; April 2018.
- 4. Eichenfeld LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis. *J Am Acad Dermatol.* 2014;71:116-132.
- 5. Nelson A, Miller A, Fleischer A, Balkrishnan R, Feldman S. How much of a topical agent should be prescribed for children of different sizes? *J Derm Treat*. 2006; 17:224-228.

Revision History

Type of Revision	Summary of Changes	Approval Date
Annual Revision	Policy was updated to reflect the existing quantity limits when a product is obtained via home delivery.	02/01/2023
	Policy was updated to reflect the availability of brand Cleocin T 1% topical solution.	

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc. and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2023 Cigna.